Ionis Pharmaceuticals (FRA:ISI) Other Long Term Assets : €97.5 Mil (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Other Long Term Assets?

Ionis Pharmaceuticals's other long-term assets for the quarter that ended in Mar. 2024 was €97.5 Mil.

Ionis Pharmaceuticals's quarterly other long-term assets declined from Sep. 2023 (€97.5 Mil) to Dec. 2023 (€96.5 Mil) but then increased from Dec. 2023 (€96.5 Mil) to Mar. 2024 (€97.5 Mil).

Ionis Pharmaceuticals's annual other long-term assets increased from Dec. 2021 (€36.8 Mil) to Dec. 2022 (€71.1 Mil) and increased from Dec. 2022 (€71.1 Mil) to Dec. 2023 (€96.5 Mil).

Ionis Pharmaceuticals Other Long Term Assets Historical Data

The historical data trend for Ionis Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Other Long Term Assets Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

299.87

41.13

36.81

71.13

96.54

Ionis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															73.13	79.40	97.53	96.54	97.55

Ionis Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Ionis Pharmaceuticals (FRA:ISI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (FRA:ISI) Headlines

No Headlines